Healthcare technology group NetScientific plc (LON:NSCI) has made a number of appointments to its newly formed scientific advisory board (SAB) at its portfolio company Vortex Biosciences.
The board comprises of distinguished clinicians and bioengineers in the field of oncology and circulating tumour cells (CTC).
It will provide strategic guidance in decision-making to support the development and commercialization of Vortex's CTC enrichment system for both the research and diagnostic markets.
"We are thrilled to have attracted some of the world's leading experts in circulating tumor cells, oncology, clinical trials and microfluidics to help us define our clinical strategy as we commercialize our next generation CTC enrichment system, the VTX-1," said Vortex chief executive Gene Walther.
"The formation of our SAB serves as an endorsement of the scientific and clinical enthusiasm for the Vortex technology."